Barrier Therapeutics, Inc.
600 College Road East, Suite 3200
Princeton
New Jersey
08540
U.S.A.
Phone:
609-945-1200
Fax:
609-945-1212
|
Presentation Objective
Barrier Therapeutics is an emerging specialty pharmaceutical company focused on dermatology, that was "born an adolescent" with its initial financing in May 2002. Barrier has 10 products in clinical development, 3 in preclinical, and several classes of molecules for screening via a worldwide exclusive license from J&J. Because of its advanced stage of development and short corporate history, the company is accelerating its public presence among potential investors, potential corporate partners, and the investment banking community. Our presentation at this conference is an excellent venue to reach all of these priority audiences.
Corporate Mission
Barrier Therapeutics, Inc. is an emerging specialty pharmaceutical company whose mission is to become the leader in the development and commercialization of therapeutically advanced pharmaceuticals to meet unmet or underserved clinical needs in the field of dermatology. Barrier plans to manage directly all aspects of its compounds' development through NDA filings in North America and Europe and plans to field a dedicated specialty sales force in the U.S. and selected European countries while collaborating in other territories for broader market coverage.
Proprietary Technology
Barrier's initial portfolio of products under development and research pipeline are the result of a worldwide exclusive royalty-free license from affiliates of Johnson & Johnson. The clinical pipeline includes four products in or entering Phase III trials to treat fungal infections, Candida-associated diaper dermatitis, seborrheic dermatitis, and congenital ichthyosis. Six earlier-stage clinical products, of which two are late stage Phase II products, are in the areas of psoriasis, acne, skin inflammation, fungal infections, allergies, and wound healing. The Company's product portfolio also includes an orally available vitamin D3 derivative, which was recently in-licensed from RIMAC, along with numerous compounds in pre-clinical development and several classes of molecules for continued screening and exploration.
Corporate Alliances
The founding of the Company was based on the extensive product and patent portfolio, which was licensed to Barrier from affiliates of Johnson & Johnson in exchange for equity. The worldwide exclusive royalty free license to all products covers the field of dermatology, which includes diseases of the skin, hair, nails, and oral and genital mucosa. The license covers a strong patent portfolio including 25 issued U.S. patents, 6 pending U.S. patents and numerous foreign issued and pending patents.Barrier is interested in establishing strategic partners outside the United States and Canada for its portfolio.
Products
Product 1
Name: Zimycan
Indication: Candida-associated Diaper dermatitis
Phase: III
Milestone: First MRP Approval Q4 03; US Phase III data, Q1 04
Product 2
Name: Seboride
Indication: Seborrheic Dermatitis
Phase: III
Milestone: Phase III Data Q4 '03
Product 3
Name: Sporamelt (Itraconazole)
Indication: Once a day for athlete's foot; nail fungus, vulvo-vaginal candidosis
Phase: III
Milestone: Commence Phase III in VVC, Q4 03
Product 4
Name: Liarozole
Indication: Ichthyosis
Phase: III
Milestone: Initiate final studies in Europe
Product 5
Name: Rambazole
Indication: Psoriasis, Acne
Phase: I/II
Milestone: Psoriasis/Acne Phase - Proof of Principle Q1 04
Product 6
Name: Azoline
Indication: Skin Mycosis
Phase: Phase I
Milestone: Complete dose escalation Phase I - Q1 04
Product 7
Name: Ecalcidene
Indication: Psoriasis/Acne
Phase: Pre-IND
Milestone Single dose effect on TH1 and Th2 cytokines in humans
This Year's Highlights
Highlight #1: Commencement of two pivotal phase III trials with Seboride in seborrheic dermatitis and final Phase III with Zimycan in Candida-associated diaper dermatitis.
Highlight #2: License from RIMAC of orally available Vitamin D3 derivative, Ecalcidene, for potential use in psoriasis, osteoporosis, organ transplant rejection, and chronic inflammatory disorders.
Highlight #3: Receipt of Orphan drug designation from EMEA for Liarozole in Congenital ichthyosis.
Anticipated Highlights
Highlight #1: Initial data from two Phase III trials with Seboride in seborrheic dermatitis - Q4 03 and for Zimycan in Candida-associated diaper dermatitis - Q1 04
Highlight #2: First approval under MRP for Zimycan in Europe.
Highlight #3: Commence Phase III clinicals in US with Sporamelt for vulvo Vaginal Candidosis.
Experience as a Partner:
In its short history, Barrier Therapeutics Inc. has entered into a number of strategic partnerships and alliances. Examples include:
Strategic Consulting Agreements
Government Grants
In-licensing (IP)
Distributor Agreements
Last Updated: 03-05-04
Email:
cmclaughlin@barriertherapeutics.com
Ownership:
Web Site:
Barrier Therapeutics, Inc.
Employees:
21 employees in U.S. ; 17 employees in Belgium
Symbol: BTRX
|
|
|
Company News |
Stiefel Laboratories Reaps First Fruits of Barrier Therapeutics, Inc. (BTRX) Acquisition With Completion of Pivotal Phase III Clinical Trial for 200 mg Hyphanox(TM) (Itraconazole) Tablet
6/2/2009 11:26:44 AM
More...
|
Stiefel Laboratories Completes Acquisition of Barrier Therapeutics, Inc. (BTRX)
8/6/2008 5:08:01 PM
More...
|
Stiefel Laboratories Successfully Completes Tender Offer for Shares of Barrier Therapeutics, Inc. (BTRX)
8/5/2008 11:06:45 AM
More...
|
Stiefel Laboratories Successfully Completes Tender Offer for Shares of Barrier Therapeutics, Inc. (BTRX)
8/5/2008 9:42:18 AM
More...
|
Stiefel Laboratories Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc. (BTRX)
7/29/2008 9:28:15 AM
More...
|
Barrier Therapeutics, Inc. (BTRX) Introduces Dual-Component Xolegel CorePak(TM) for Seborrheic Dermatitis
7/28/2008 9:33:11 AM
More...
|
Stiefel Laboratories Commences Tender Offer to Acquire Barrier Therapeutics, Inc. (BTRX)
7/8/2008 8:33:21 AM
More...
|
Barrier Therapeutics, Inc. (BTRX) and Stiefel Laboratories Sign Definitive Merger Agreement
6/23/2008 7:11:52 AM
More...
|
Barrier Therapeutics, Inc. (BTRX) Announces First Quarter 2008 Financial Results
4/30/2008 11:10:19 AM
More...
|
Barrier Therapeutics, Inc. (BTRX) to Present At the Deutsche Bank (DB) 33rd Annual Health Care Conference
4/28/2008 10:11:33 AM
More...
|
|
|
|